AACE Annual Meeting

Continuing Medical Education Information

Event start date: 05/09/2024
Credit claim deadline: 12/31/2024


Statement of Need

AACE 2024 Annual Meeting is designed to provide Endocrinologists and Patient Care Team Members with practical applications of the most current practice guidance and the latest scientific discovery in the diagnosis and treatment for endocrine-related disorders.


Target Audience

This program is intended for medical professionals from the field of clinical endocrinology at all stages in their career including clinical endocrinologists, primary care physicians, physician assistants, nurse practitioners, nurses, pharmacists, registered dietitians, medical students, residents, and fellows in training. 


Learning Objectives

By the end of the meeting, participants will be able to:

  • Discuss the latest scientific and clinical discoveries in the field of endocrinology, diabetes, and metabolism. 
  • Apply newfound knowledge to diagnosis and management for improved patient outcomes. 
  • Assess the potential applications of emerging scientific advances that affect the practice of endocrinology. 
  • Empower participants to educate their patients regarding clinical treatment options. 


Accreditation and Designation Statements


The American College of Endocrinology (ACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American College of Endocrinology (ACE) designates this “Other” (live and on demand) for a maximum of 51 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit

Provider approved by the California Board of Registered Nursing, Provider Number 17762, for 51 contact hours.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 51 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Only those who receive a passing score will be eligible for MOC credit. 

Please allow two weeks for MOC points to appear within your account on the ABIM website. Participation information will be shared. 


Applicants for certification through the American Board of Obesity Medicine (ABOM) may claim up to 7.75 Group Two CME credits toward the ABOM requirement when providing a CME certificate or transcript that shows attendance at the obesity and nutrition track sessions.


Disclosure and Conflicts of Interest Policy

The American Association of Clinical Endocrinologists (AACE) remains strongly committed to providing the best available evidence based clinical information to participants of this educational activity and requires an open disclosure of any potential conflict of interest identified by our faculty members. It is not the intent of AACE to eliminate all situations of potential conflict of interest, but rather to enable those who are working with AACE to recognize situations that may be subject to question by others. All disclosed conflicts of interest are reviewed by the CME Subcommittee to ensure that such situations are properly evaluated and, if necessary, resolved. AACE educational standards pertaining to conflict of interest are intended to maintain the professional autonomy of the clinical experts inherent in promoting a balanced presentation of science. Through our review process, all AACE accredited activities are ensured of independent, objective, scientifically balanced presentations of information. Disclosure of any or no relationships will be made available for all educational activities. 


Commercial Supporters

This activity is supported by educational grants from the following:

  • Amgen
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Medtronic
  • Radius Pharmaceuticals


In Kind Support:

The Thyroid Ultrasound Workshop was supported by In Kind Support from:

  • Esaote - Ultrasound Machines
  • RGS Healthcare - Ultrasound Machines
  • Clarius Mobile Health - Ultrasound Machines
  • GE Healthcare - Ultrasound Machines

The Diabetes Technology Skills Workshop was supported by In Kind Support from:

  • Tandem - Insulin Pumps
  • Insulet - Insulin Pumps
  • Medtronic - Insulin Pumps, Insulin Pens, Glucose Monitors
  • Dexcom - Glucose Monitors
  • Ascensia - Glucose Monitor Demonstration Kits
  • Abbott Diabetes Care - Glucose Monitors
  • MannKind - Insulin Patch
  • CeQur - Insulin Patch
  • Intuity Medical - Glucose Monitoring Kits
  • Beta Bionics - Insulin Pumps


Planning Committee Disclosures

Planner Name

Betul Hatipoglu, MD

Ineligible Company


Relevant Financial Relationship

Research Funding
Research Funding

Planner Name

Adriana Ioachimescu, MD, PhD, FACE

Ineligible Company

Xeris Pharmaceuticals
Recordati Rare Diseases

Relevant Financial Relationship

Research Funding; Consultant
Research Funding; Consultant
Research Funding; Consultant

Planner Name

Cecilia Low Wang, MD, FACE

Ineligible Company

Virta Health

Relevant Financial Relationship

Research Funding
Research Funding

Planner Name

Archana Sadhu, MD, FACE

Ineligible Company

Abbott Laboratories

Relevant Financial Relationship


Planner Name

Alex Tessnow, MD, ECNU, FACE

Ineligible Company

Horizon Pharmaceutical
Spectrix Therapeutics

Relevant Financial Relationship



All of the relevant financial relationships listed for these individuals have been mitigated. All other planners for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.


None of the reviewers for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.


Faculty Disclosures

View our 2024 faculty disclosures.

View Faculty Disclosures